KURA
Price
$9.12
Change
-$0.62 (-6.37%)
Updated
Dec 18, 04:59 PM (EDT)
64 days until earnings call
LQDA
Price
$10.70
Change
-$0.61 (-5.39%)
Updated
Dec 18, 04:59 PM (EDT)
85 days until earnings call
Ad is loading...

KURA vs LQDA

Header iconKURA vs LQDA Comparison
Open Charts KURA vs LQDABanner chart's image
Kura Oncology
Price$9.12
Change-$0.62 (-6.37%)
Volume$41.45K
CapitalizationN/A
Liquidia
Price$10.70
Change-$0.61 (-5.39%)
Volume$18.79K
CapitalizationN/A
KURA vs LQDA Comparison Chart
Loading...
KURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KURA vs. LQDA commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KURA is a Hold and LQDA is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (KURA: $9.74 vs. LQDA: $11.31)
Brand notoriety: KURA and LQDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KURA: 79% vs. LQDA: 49%
Market capitalization -- KURA: $757.42M vs. LQDA: $957.24M
KURA [@Biotechnology] is valued at $757.42M. LQDA’s [@Biotechnology] market capitalization is $957.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KURA’s FA Score shows that 1 FA rating(s) are green whileLQDA’s FA Score has 0 green FA rating(s).

  • KURA’s FA Score: 1 green, 4 red.
  • LQDA’s FA Score: 0 green, 5 red.
According to our system of comparison, LQDA is a better buy in the long-term than KURA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KURA’s TA Score shows that 5 TA indicator(s) are bullish while LQDA’s TA Score has 6 bullish TA indicator(s).

  • KURA’s TA Score: 5 bullish, 3 bearish.
  • LQDA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both KURA and LQDA are a good buy in the short-term.

Price Growth

KURA (@Biotechnology) experienced а -5.34% price change this week, while LQDA (@Biotechnology) price change was +5.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

KURA is expected to report earnings on Feb 20, 2025.

LQDA is expected to report earnings on Mar 13, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LQDA($906M) has a higher market cap than KURA($709M). LQDA YTD gains are higher at: -5.985 vs. KURA (-32.267). LQDA has higher annual earnings (EBITDA): -107.21M vs. KURA (-195.08M). KURA has more cash in the bank: 455M vs. LQDA (204M). LQDA has less debt than KURA: LQDA (2.69M) vs KURA (16.6M). LQDA has higher revenues than KURA: LQDA (15.6M) vs KURA (0).
KURALQDAKURA / LQDA
Capitalization709M906M78%
EBITDA-195.08M-107.21M182%
Gain YTD-32.267-5.985539%
P/E RatioN/AN/A-
Revenue015.6M-
Total Cash455M204M223%
Total Debt16.6M2.69M617%
FUNDAMENTALS RATINGS
KURA vs LQDA: Fundamental Ratings
KURA
LQDA
OUTLOOK RATING
1..100
5515
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
68
Overvalued
PROFIT vs RISK RATING
1..100
10040
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
9444
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KURA's Valuation (28) in the Biotechnology industry is somewhat better than the same rating for LQDA (68) in the Pharmaceuticals Major industry. This means that KURA’s stock grew somewhat faster than LQDA’s over the last 12 months.

LQDA's Profit vs Risk Rating (40) in the Pharmaceuticals Major industry is somewhat better than the same rating for KURA (100) in the Biotechnology industry. This means that LQDA’s stock grew somewhat faster than KURA’s over the last 12 months.

KURA's SMR Rating (97) in the Biotechnology industry is in the same range as LQDA (98) in the Pharmaceuticals Major industry. This means that KURA’s stock grew similarly to LQDA’s over the last 12 months.

LQDA's Price Growth Rating (44) in the Pharmaceuticals Major industry is somewhat better than the same rating for KURA (94) in the Biotechnology industry. This means that LQDA’s stock grew somewhat faster than KURA’s over the last 12 months.

LQDA's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as KURA (100) in the Biotechnology industry. This means that LQDA’s stock grew similarly to KURA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KURALQDA
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 24 days ago
78%
Bullish Trend 2 days ago
86%
Declines
ODDS (%)
Bearish Trend 6 days ago
83%
Bearish Trend 9 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 3 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
KURA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MTCCX54.80N/A
N/A
MFS Technology C
STPCX11.99-0.04
-0.33%
Saratoga Technology & Comm C
PGOYX77.82-0.27
-0.35%
Putnam Large Cap Growth Y
ECFVX19.57-0.14
-0.71%
Eaton Vance Focused Value Opps C
REBYX30.02-0.33
-1.09%
Russell Inv US Small Cap Equity Y

KURA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KURA has been loosely correlated with PYXS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KURA jumps, then PYXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KURA
1D Price
Change %
KURA100%
-2.36%
PYXS - KURA
43%
Loosely correlated
-2.98%
AXON - KURA
41%
Loosely correlated
-2.09%
PSTX - KURA
35%
Loosely correlated
-0.11%
EVAX - KURA
35%
Loosely correlated
-8.92%
ZYME - KURA
34%
Loosely correlated
-2.90%
More

LQDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LQDA has been loosely correlated with ALNY. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if LQDA jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LQDA
1D Price
Change %
LQDA100%
+2.54%
ALNY - LQDA
37%
Loosely correlated
+1.06%
AXON - LQDA
32%
Poorly correlated
-2.09%
AVXL - LQDA
30%
Poorly correlated
+0.33%
KURA - LQDA
29%
Poorly correlated
-2.36%
CRSP - LQDA
29%
Poorly correlated
+0.88%
More